FindTrial
Sign In

The Comparative Study of [68Ga]-Exendin-4 and [68Ga]-DOTANOC PET/CT for Imaging of Insulinoma

The Clinical Research of Exendin-4 PET/CT for Imaging of Insulinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074467
Enrollment
Unknown
Registered
2023-08-08
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulinoma

Interventions

Gold Standard:pathology (operation or biopsy) and follow-up with conventional imaging
Index test:SUVmax, detection rate, sensitivity, specificity, accuracy. [68Ga]-Exendin-4 and [68Ga]-DOTANOC PET/CT for Imaging of Insulinoma

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Age>13y, (2) Patients with recurrent hypoglycaemia, (3) Patients diagnosed pathologically as neuroendocrine tumor and diagnosed clinically as insulinoma, and with the suspicious lesions in conventional imaging, (4) Signed written consent

Exclusion criteria

Exclusion criteria: (i) Pregnancy woman; (2) Patients who did not willing to participant in this study or did not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
detection rate;sensitivity;specificity;accuracy;SUVmax;Accuracy ;Sensitivity ;Specificity ;—

Secondary

MeasureTime frame
Progression free survival;SUVmax;—

Countries

China

Contacts

Public ContactSong Shaoli

Fudan University Shanghai Cancer Center

shaoli-song@163.com+86 138 1660 8573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026